Citadel Advisors
IGC icon

Citadel Advisors’s IGC Pharma IGC Stock Holding History

Citadel Advisors’s Portfolio IGC Stock Details IGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,800
Closed -$3.63K – 14978
2024
Q4 		$3.63K Sell
10,800
-7,900
-42% -$2.96K ﹤0.01% 13985
2024
Q3 		$7.98K Hold
18,700
– – ﹤0.01% 13327
2024
Q2 		$8.11K Buy
+18,700
New +$9.3K ﹤0.01% 13211
2024
Q1 		– Sell
-10,800
Closed -$3.02K – 14981
2023
Q4 		$3.02K Hold
10,800
– – ﹤0.01% 13636
2023
Q3 		$3.88K Hold
10,800
– – ﹤0.01% 13539
2023
Q2 		$3.37K Hold
10,800
– – ﹤0.01% 13699
2023
Q1 		$3.67K Sell
10,800
-101,500
-90% -$38.1K ﹤0.01% 14021
2022
Q4 		$35.7K Sell
112,300
-26,300
-19% -$10.7K ﹤0.01% 12540
2022
Q3 		$60K Buy
138,600
+5,400
+4% +$2.88K ﹤0.01% 11499
2022
Q2 		$71K Buy
133,200
+15,400
+13% +$9.71K ﹤0.01% 11693
2022
Q1 		$112K Hold
117,800
– – ﹤0.01% 12165
2021
Q4 		$115K Sell
117,800
-65,200
-36% -$87.5K ﹤0.01% 12574
2021
Q3 		$271K Sell
183,000
-29,400
-14% -$47.5K ﹤0.01% 11278
2021
Q2 		$348K Buy
212,400
+500
+0.2% +$763 ﹤0.01% 10902
2021
Q1 		$379K Buy
211,900
+154,900
+272% +$281K ﹤0.01% 10313
2020
Q4 		$89K Sell
57,000
-33,000
-37% -$48.8K ﹤0.01% 10288
2020
Q3 		$94K Buy
+90,000
New +$91.5K ﹤0.01% 9300

Other funds holding IGC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
LC
Lawood & Co Williamsport, Pennsylvania $148M AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors's IGC Position: Q1 2026 in Review

Citadel Advisors sold out of IGC Pharma (IGC) in Q1 2026, closing a stake of 277,594 shares — an estimated $78.1K sold.

Citadel Advisors first reported a position in IGC in Q4 2013 and held it in 30 quarters. The position peaked at $262K in Q3 2025. 35 funds tracked by Wall St. Rank hold IGC as of Q1 2026.

  • Citadel Advisors reported no remaining IGC Pharma position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 277,594 IGC Pharma shares in Q1 2026, an estimated $78.1K.
  • Citadel Advisors first reported a position in IGC Pharma in Q4 2013 and held it in 30 quarters.
  • Citadel Advisors's IGC Pharma position peaked at $262K in Q3 2025.
  • 35 funds tracked by Wall St. Rank held IGC Pharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.